Methods for preparing purified lipopeptides

a technology of lipopeptides and purified water, which is applied in the direction of peptide/protein ingredients, drug compositions, antibacterial agents, etc., can solve the problems of no simple and robust method, no method disclosed in these u.s. patents, and no effective method

Inactive Publication Date: 2006-01-19
CUBIST PHARMA INC
View PDF36 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The instant invention addresses these problems by providing crystalline and crystalline-like forms of lipopeptides, particularly daptomycin and daptomycin-related lipopeptides and methods for producing them. In one embodi

Problems solved by technology

None of these U.S. patents discloses a method for precipitating or crystallizing a lipopeptide in a manner to increase purity of the lipopeptide.
However, there has been no simple and robust method tha

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for preparing purified lipopeptides
  • Methods for preparing purified lipopeptides
  • Methods for preparing purified lipopeptides

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0135] Daptomycin was prepared by conventional techniques. The daptomycin preparation was a pale yellow amorphous powder, with a solubility at 25° C. of greater than 1 g / mL in water and a solubility of 2.8 mg / mL in ethanol. The amorphous daptomycin preparation was hygroscopic and decomposed at 215° C.

[0136] The remaining examples describe crystallizing or precipitating lipopeptides in the presence or absence of an organic precipitant (e.g., PEG).

example 2

[0137] In a microbatch crystallization, 25 μL of a daptomycin stock (20 mg / mL in methanol) was sequentially mixed with 15 μL of reagent stock (200 mM calcium acetate, 0.1 M cacodylate (pH 6.5), 18% [w / v] PEG 8000 and 15 μL ethylene glycol) to give a solution that was 27.5% aqueous component, 45% methanol and 27.5% ethylene glycol. Urchin-like crystals were formed at a yield of 50% with a purity of 98% as measured by HPLC.

example 3

[0138] A daptomycin stock was prepared by dissolving 440 mg daptomycin in 1 mL of a buffer containing 25 mM sodium acetate (pH 5.0) and 5 mM CaCl2. Crystallization was done by the vapor diffusion (hanging drop) method, in which 5 μL of the daptomycin stock was added to 5 μL of 0.1 M tri-sodium citrate dihydrate (pH 5.6), and 35% [v / v] tert-butanol in water to form a drop. The drop was suspended over a reservoir solution (0.1 M tri-sodium citrate dihydrate (pH5.6), and 35% [v / v] tert-butanol in water) in an=air-tight-environment until crystallization occurred. This method yielded urchin-like daptomycin crystals. See, e.g., FIG. 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application claims the benefit of U.S. Provisional Application No. 60 / 256,268, filed Dec. 18, 2000; Ser. No. 60 / 274,741, filed Mar. 9, 2001; Ser. No. filed Dec. 13, 2001; and Ser. No. filed Dec. 13, 2001, the contents of which are incorporated herein by reference.TECHNICAL FIELD OF THE INVENTION [0002] The present invention relates to crystalline and crystalline-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to processes for preparing crystalline or crystal-like forms of the lipopeptide and to methods of purifying lipopeptides including daptomycin. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions. BACKGROUND OF THE INVENTION [0003...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/12C07K7/64
CPCA61K38/00C07K7/66C07K11/02C07K7/08
Inventor KEITH, DENNISLAI, JAN-JIGOVARDHAN, CHANDRIKAKHALAF, NAZER
Owner CUBIST PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products